JP

Takeshi Doi

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takeshi Doi. Retrieved from https://idiyas.com/inventor/takeshi-doi-rbxac56s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: The Innovations of Takeshi Doi

Introduction

Takeshi Doi is a notable inventor based in Japan. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant proteins. His work has implications for various therapeutic applications.

Latest Patents

Takeshi Doi holds a patent for the "Recombinant B-Chain Of The IL-2 Receptor - Recombinant IL-21R.beta. chain or portions thereof, cDNA coding therefore, vectors containing said cDNA, hosts transfected by said vectors, and monoclonal antibodies to said recombinant IL-2R.beta. or portions thereof." This innovation showcases his expertise in genetic engineering and protein synthesis.

Career Highlights

Throughout his career, Takeshi Doi has worked with various companies, including Mitsuru Tsudo. His experience in the industry has allowed him to develop and refine his inventions, contributing to advancements in medical science.

Collaborations

Takeshi Doi has collaborated with notable individuals in his field, including Takeshi Kono and Seijiro Minamoto. These partnerships have fostered innovation and have been instrumental in the progress of his research.

Conclusion

Takeshi Doi's contributions to biotechnology and his innovative patents highlight his role as a significant figure in the field. His work continues to influence advancements in medical therapies and genetic research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…